{"id":9401,"date":"2025-09-02T14:36:59","date_gmt":"2025-09-02T12:36:59","guid":{"rendered":"https:\/\/www.api.parlonsfinance.fr\/?p=9401"},"modified":"2025-09-03T12:34:37","modified_gmt":"2025-09-03T10:34:37","slug":"novo-nordisk-du-sommet-boursier-a-la-tourmente","status":"publish","type":"post","link":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/","title":{"rendered":"Novo Nordisk du sommet boursier \u00e0 la tourmente"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">650 Mds $ de valorisation boursi\u00e8re en 2024, \u201360 % en moins d\u2019un an : Novo Nordisk victime de sp\u00e9culation\u2026 ou d\u2019une vraie d\u00e9gradation de ses fondamentaux ?\u2028<\/h2>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"848\" height=\"342\" src=\"https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/unnamed-3.jpg\" alt=\"\" class=\"wp-image-9429\" srcset=\"https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/unnamed-3.jpg 848w, https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/unnamed-3-300x121.jpg 300w, https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/unnamed-3-768x310.jpg 768w, https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/unnamed-3-585x236.jpg 585w\" sizes=\"auto, (max-width: 848px) 100vw, 848px\" \/><\/figure>\n\n\n\n<p>Pour comprendre cette baisse, il faut s&rsquo;int\u00e9resser au march\u00e9 du traitement contre l&rsquo;ob\u00e9sit\u00e9, principal moteur de la valorisation de Novo.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Deux r\u00e9visions successives \u00e0 la baisse des pr\u00e9visions de r\u00e9sultats pour 2025, ce qui a fortement r\u00e9duit la confiance des investisseurs.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Annonce du d\u00e9part anticip\u00e9 du CEO Lars Fruergaard J\u00f8rgensen le 16 mai 2025<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Concurrence accrue d\u2019Eli Lilly, dont le traitement contre l\u2019ob\u00e9sit\u00e9 d\u00e9passe d\u00e9sormais celui de Novo en prescriptions aux \u00c9tats-Unis, faisant craindre une perte de terrain pour le g\u00e9ant danois.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Novo est confront\u00e9 \u00e0 des contrefa\u00e7ons de Wegovy, fabriqu\u00e9es \u00e0 partir de versions m\u00e9lang\u00e9es ou recompos\u00e9es en pharmacie<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Malgr\u00e9 ces freins :\u2028<\/strong><\/h3>\n\n\n\n<p>Novo Nordisk reste un leader du traitement de l\u2019ob\u00e9sit\u00e9 et a enregistr\u00e9 une croissance solide de +18 % de ses ventes au premier semestre 2025.<\/p>\n\n\n\n<p>Goldman Sachs estime depuis plusieurs mois que la r\u00e9action des investisseurs est exag\u00e9r\u00e9e et a \u00e9mis des recommandations d\u2019achat, tout en r\u00e9duisant ses pr\u00e9visions de hausse, jugeant que la reprise prendra plus de temps que pr\u00e9vu.<\/p>\n\n\n\n<p>La guerre de l\u2019innovation pour proposer le traitement anti-ob\u00e9sit\u00e9 le plus efficace d\u00e9terminera le futur leader mondial. Si Novo parvient \u00e0 s\u2019imposer durablement sur ce march\u00e9 estim\u00e9 \u00e0 130 Mds $ d\u2019ici 2030 (Goldman Sachs), son titre pourrait retrouver une trajectoire de hausse.<br>\u2028<br>Selon vous, Novo Nordisk r\u00e9ussira-t-il \u00e0 conserver son avance face \u00e0 la concurrence grandissante d\u2019Eli Lilly ?<\/p>\n\n\n\n<p>Sources : <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>World Health Organization (OMS)<\/strong> sur l\u2019ob\u00e9sit\u00e9 : <a href=\"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight?utm_source=chatgpt.com\">https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight<\/a><\/li>\n\n\n\n<li><strong>FDA (Food &amp; Drug Administration)<\/strong> pour les autorisations de traitements : <a>https:\/\/www.fda.gov\/drugs<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>650 Mds $ de valorisation boursi\u00e8re en 2024, \u201360 % en moins d\u2019un an : Novo Nordisk victime de sp\u00e9culation\u2026 ou d\u2019une vraie d\u00e9gradation de ses fondamentaux ?\u2028 Pour comprendre cette baisse, il faut s&rsquo;int\u00e9resser au march\u00e9 du traitement contre l&rsquo;ob\u00e9sit\u00e9, principal moteur de la valorisation de Novo. Malgr\u00e9 ces freins :\u2028 Novo Nordisk reste [&hellip;]<\/p>\n","protected":false},"author":83,"featured_media":9428,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[793,29,4],"tags":[72,7,5,23,109],"class_list":["post-9401","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-highlighted","category-entreprises","category-nos-analyses","tag-banque","tag-business","tag-finance","tag-investissement","tag-trading"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/posts\/9401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/users\/83"}],"replies":[{"embeddable":true,"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/comments?post=9401"}],"version-history":[{"count":5,"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/posts\/9401\/revisions"}],"predecessor-version":[{"id":9441,"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/posts\/9401\/revisions\/9441"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/media\/9428"}],"wp:attachment":[{"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/media?parent=9401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/categories?post=9401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/tags?post=9401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}